|
Syncona Ltd said on Wednesday it invested $54 million in neurological disorder-focused gene therapy company SwanBio Therapeutics' Series B financing round.
The investor in healthcare companies said the proceeds will primarily be used to aid SwanBio's ongoing clinical development of its lead candidate, SBT101, for adrenomyeloneuropathy.
Following the drawdown of SwanBio's Series B financing, which totals $56 million including investment from Mass General Brigham Ventures, Syncona's ownership stake will be 80%. This includes the drawdown of the first tranche investment of $19 million. Syncona's holding value of SwanBio is now £96 million.
Syncona shares were up 4.9% at 179.56 pence each on Wednesday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
